AbbVie shares fall around 1.5% as strong Q2 2026 results fail to lift sentiment

Traders Union
All News
Stocks
AbbVie slides 1.55% today

Highlights

AbbVie posted strong second-quarter 2026 earnings, raised its full-year EPS guidance, and sustained a $1.73 per share dividend.
The $8.7 billion Cerevel Therapeutics acquisition added neuroscience assets, as Citadel acquired 2.7 million AbbVie shares in Q2 2026.
Shares of AbbVie trade in a bullish trend above key moving averages, with a forecast range of $258.4 to $264.95 over the next five days.

Earnings strength and acquisitions offset by institutional flows and layoffs

AbbVie reported strong second-quarter 2026 earnings and raised its full-year EPS guidance. The company maintained a quarterly dividend payout of $1.73 per share and completed its $8.7 billion acquisition of Cerevel Therapeutics on August 1, 2024, expanding its neuroscience assets. Citadel, managed by Ken Griffin, acquired 2.7 million shares during Q2 2026 and AbbVie announced layoffs affecting 85 staff in Irvine, California, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees worrying signs behind the recent slide in AbbVie stock. He notes that despite strong quarterly figures and increased EPS guidance, institutional buying and M&A headlines have not prevented selling pressure. The current price sits uncomfortably near session lows while overbought indicators flash warnings. He remains skeptical about the sustainability of the bullish technical setup, especially with broad momentum signals contradicting near-term weakness after the open. "I see significant downside risk if AbbVie falls below $260.38 — market enthusiasm looks overstretched and sensitive to profit-taking."

Viktoras Karapetjanc, expert at Traders Union, focuses on the strong fundamentals supporting AbbVie. He highlights impressive earnings, a raised EPS outlook, and the rapid integration of Cerevel's neuroscience assets as key positives. Institutional flows, such as Citadel's recent large acquisition, signal ongoing confidence despite the modest layoff announcement. Karapetjanc believes the bullish structure remains intact, with momentum and buy signals pointing to further upside once the short-term overbought phase is absorbed. "I expect AbbVie to maintain its uptrend, and a break above $263.25 could quickly push the stock toward new highs."

Jainam Mehta, market strategist, sees mixed technical and macro signals at play. He points out AbbVie is currently showing firm trend strength above key moving averages, yet overbought conditions could trigger short-term pullbacks. Mehta notes that volatility likely keeps price in a $258.40 to $264.95 corridor for now. "If the stock breaks above $263.25, I’d watch for breakout momentum — but a failure here may give tactical sellers a window for contrarian trades."

Bullish technical structure challenged by overbought signals and volatility

AbbVie is trading above its 20-day, 50-day, and 200-day moving averages ($253.81, $249.55, $227.05), indicating sustained bullish momentum across short-, medium-, and long-term horizons. The next key levels are near-term ceiling at $263.25 and a floor at $260.38, reinforcing the stock's firmly established uptrend with MA alignment also categorized as bullish. Momentum readings are strong: the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) both generate Buy readings, pointing to continued positive drive. The Relative Strength Index (RSI) at 64.67 signals a bias toward buying pressure. However, the Stochastic RSI and Commodity Channel Index (CCI) both indicate overbought conditions, joined by Bull/Bear Power (BBP) reading of 8.48, confirming buyer dominance but also flagging an overbought setup. The Awesome Oscillator (AO) is positive, supporting the ongoing bullish tone. After opening with a downside gap of about 0.3% and slipping $4.13 or 1.55% to $261.66, the stock is trading near session lows. Intraday volatility stands at 0.66%, and the stock is currently under moderate pressure after the open. Most momentum signals confirm recent buyers' advantage, though overbought conditions could curb further upside in the near term.

Earlier, analysts noted that AbbVie's bullish technical momentum and strategic acquisitions positioned the stock for further gains. The current analysis adds that while technical signals remain supportive, traders should monitor a break above $263.25 or below $260.38 for confirmation of near-term direction within the projected volatility band.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.